Search | Clinical Trials Finder

Conditions: Pancreatic Neoplasms, Peutz-Jegher's Syndrome, BRCA1 Gene Mutation, BRCA2 Gene Mutation, Ataxia Telangiectasia, Familial Atypical Mole-Malignant Melanoma Syndrome, Colorectal Neoplasms, Hereditary Nonpolyposis, Hereditary Pancreatitis
Interventions: Pancreatic Cancer Screening Pathway 1, Pancreatic Cancer Screening Pathway 2; Other
Lead sponsor: University of Arkansas; Other
Eligibility: 18 Years to 99 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Prostate Cancer, BRCA1 Mutation, BRCA2 Mutation, Prostatic Adenocarcinoma, High-Risk Cancer
Interventions: Olaparib, LHRH agonist; Drug
Lead sponsor: Rana McKay, MD; Other
Eligibility: 18 Years and older · Male only
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 6
States / cities: La Jolla, California • Baltimore, Maryland • New York, New York + 2 more

Conditions: Breast Cancer
Interventions: Questionnaires to Evaluate Anxiety Related to Genetic Testing; Other
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years and older · Female only
Enrollment: 164 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2027
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: BRCA1 Mutation, BRCA2 Mutation
Interventions: Disclosure Toolkit; Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: BRCA1 Mutation Carrier, BRCA2 Mutation Carrier, Endometrial Adenocarcinoma, Estrogen Receptor Negative, HER2/Neu Negative, High Grade Ovarian Serous Adenocarcinoma, Progesterone Receptor Negative, Recurrent Breast Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Recurrent Uterine Corpus Carcinoma, Stage III Uterine Corpus Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7, Stage IV Uterine Corpus Cancer AJCC v7, Triple-Negative Breast Carcinoma
Interventions: Capivasertib, Laboratory Biomarker Analysis, Olaparib, Pharmacological Study, Vistusertib; Drug · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 159 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Breast Cancer, BRCA1 Mutation, BRCA2 Mutation, Ovarian Cancer
Interventions: RealRisks, BNAV, iNYP, Standard Educational Material, High-Risk Message; Other
Lead sponsor: Columbia University; Other
Eligibility: 21 Years to 75 Years · Female only
Enrollment: 276 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Breast Cancer
Interventions: Physician Counseling; Behavioral
Lead sponsor: Baystate Medical Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 1
States / cities: Springfield, Massachusetts

Conditions: Atypical Ductal Breast Hyperplasia, Atypical Lobular Breast Hyperplasia, BRCA1 Mutation Carrier, BRCA2 Mutation Carrier, Ductal Breast Carcinoma in Situ, Lobular Breast Carcinoma in Situ
Interventions: counseling intervention, behavioral dietary intervention, exercise intervention, questionnaire administration, laboratory biomarker analysis; Other · Behavioral
Lead sponsor: University of Washington; Other
Eligibility: 35 Years to 65 Years · Female only
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2013
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: BRCA1 Gene Mutation, BRCA2 Gene Mutation, RAD51C Gene Mutation, RAD51D Gene Mutation, BRIP1 Gene Mutation, Ovarian Cancer
Interventions: Risk-reducing salpingectomy with delayed oophorectomy, Risk-reducing salpingo-oophorectomy; Procedure
Lead sponsor: University Medical Center Nijmegen; Other
Eligibility: 25 Years to 50 Years · Female only
Enrollment: 3,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2040
U.S. locations: 11
States / cities: Chicago, Illinois • Boston, Massachusetts • Rochester, Minnesota + 6 more

Conditions: Basal-Like Breast Carcinoma, BRCA1 Mutation Carrier, BRCA2 Mutation Carrier, Breast Carcinoma, Estrogen Receptor Negative, HER2/Neu Negative, Hereditary Breast and Ovarian Cancer Syndrome, Ovarian Carcinoma, Pancreatic Carcinoma, Progesterone Receptor Negative, Prostate Carcinoma, Recurrent Breast Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Solid Neoplasm, Triple-Negative Breast Carcinoma
Interventions: Laboratory Biomarker Analysis, Pharmacological Study, Veliparib; Other · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 19 Years and older
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2017
U.S. locations: 7
States / cities: Duarte, California • Los Angeles, California • Sacramento, California + 4 more

Conditions: Stage I Breast Cancer, Stage II Breast Cancer, Stage III Breast Cancer, Breast Cancer, HER2-negative Breast Cancer, Germline BRCA1 Gene Mutation, Germline BRCA2 Gene Mutation, Deleterious PALB2 Gene Mutation
Interventions: Niraparib, Dostarlimab; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 8
States / cities: New Haven, Connecticut • Baltimore, Maryland • Boston, Massachusetts + 3 more

Conditions: Adult Solid Neoplasm, BRCA1 Mutation Carrier, BRCA2 Mutation Carrier, Hereditary Breast and Ovarian Cancer Syndrome
Interventions: Carboplatin, Laboratory Biomarker Analysis, Paclitaxel, Pharmacological Study, Veliparib; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2007
U.S. locations: 7
States / cities: Duarte, California • Los Angeles, California • Sacramento, California + 3 more

Conditions: Breast Cancer, PALB2-Mutated Breast Carcinoma, HER2-negative Breast Cancer, BRCA1 Mutation, BRCA2 Mutation
Interventions: Axatilimab, Olaparib; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 2
States / cities: Boston, Massachusetts • Rochester, Minnesota

Conditions: Deleterious BRCA1 Gene Mutation, Deleterious BRCA2 Gene Mutation, Endometrial Adenocarcinoma, High Grade Ovarian Serous Adenocarcinoma, Platinum-Resistant Ovarian Carcinoma, Primary Peritoneal High Grade Serous Adenocarcinoma, Progressive Disease, Recurrent Endometrial Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
Interventions: Copanlisib, Niraparib; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Ovarian Cancer, Breast Cancer, Prostate Cancer
Interventions: LY2606368; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Neoplasms, Breast, Carcinoma of Breast, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, BRCA1 Gene Mutation, BRCA2 Gene Mutation, Ovarian Neoplasms
Interventions: niraparib, Physician's choice; Drug
Lead sponsor: Tesaro, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 216 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 25
States / cities: Tucson, Arizona • Los Angeles, California • Fort Myers, Florida + 20 more

Conditions: Breast Cancer, BRCA1 Mutation, BRCA2 Mutation
Interventions: Psychosocial variables; Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older · Female only
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Advanced Solid Tumors, Breast Cancer Recurrent, Colorectal Cancer Metastatic, Colon Cancer, Rectal Adenocarcinoma, Endometrial Cancer
Interventions: ATX-559; Drug
Lead sponsor: Accent Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 5
States / cities: Aurora, Colorado • Oklahoma City, Oklahoma • Nashville, Tennessee + 2 more

Conditions: Metastatic Breast Cancer With BRCA 1 or BRCA 2 Genetic Mutation, Triple-Negative Breast Cancer
Interventions: Veliparib, Cisplatin, Vinorelbine; Drug
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older · Female only
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Ovarian, Breast, Prostate, Pancreatic, Advanced Tumours
Interventions: olaparib; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 298 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2024
U.S. locations: 2
States / cities: West Hollywood, California • Philadelphia, Pennsylvania

Conditions: Ovarian Cancer
Interventions: BMN 673 (talazoparib); Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 99 Years · Female only
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Pancreatic Neoplasms, Ovarian Neoplasms, Breast Neoplasms, Prostatic Neoplasms
Interventions: BTP-114; Drug
Lead sponsor: Placon Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 8
States / cities: Sarasota, Florida • Boston, Massachusetts • St Louis, Missouri + 4 more

Conditions: Breast Cancer, Ovarian Cancer, Pancreas Cancer, Prostate Cancer, BRCA1 Mutation, BRCA-Mutated Ovarian Carcinoma, BRCA-Associated Breast Carcinoma, HRD Positive Advanced Ovarian Cancer
Interventions: TNG348, Olaparib; Drug
Lead sponsor: Tango Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 7
States / cities: Denver, Colorado • Orange City, Florida • Sarasota, Florida + 3 more

Conditions: Estrogen Receptor-negative Breast Cancer, HER2-negative Breast Cancer, Hereditary Breast/Ovarian Cancer - BRCA1, Hereditary Breast/Ovarian Cancer - BRCA2, Male Breast Cancer, Progesterone Receptor-negative Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer, Triple-negative Breast Cancer
Interventions: veliparib, cisplatin, vinorelbine tartrate, laboratory biomarker analysis, pharmacological study; Drug · Other
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2017
U.S. locations: 1
States / cities: Seattle, Washington

Search by objective public record fields.

Pancreatic Cancer Screening of High-Risk Individuals in Arkansas

Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With Select HRR Gene Alterations

Evaluating the Effects of Genetic Testing on Patients' Stress Levels

Evaluating Cascade Communication Methods

mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian

Decision Support for BRCA Testing in Ethnically Diverse Women

Effect of Counseling on Psychological Stress Amongst Women Felt to be at High Risk for Breast Cancer Development

Group-Based Lifestyle Intervention in Measuring Biomarker Levels in Participants at High Risk for Breast Cancer

TUBectomy With Delayed Oophorectomy in High Risk Women to Assess the Safety of Prevention

Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous Therapy

Niraparib + Dostarlimab In BRCA Mutated Breast Cancer

Veliparib, Carboplatin, and Paclitaxel in Treating Patients With Advanced Solid Cancer

Phase Ib Study of Axatilimab in Combination With Olaparib in BRCA1/2 and PALB2- Associated Metastatic HER2-negative Breast Cancer

Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

A Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) in BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, High Grade Serous Ovarian Cancer, and Metastatic Castrate-Resistant Prostate Cancer

A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients

Depression and Body Image Distress Following Mastectomy With Reconstruction

First-in-Human Study of ATX-559, an Oral Inhibitor of DHX9, in Patients With Advanced or Metastatic Solid Tumors, and Molecularly Defined Cancers

Expanded Access With ABT-888 (Veliparib) to Treat Metastatic Breast Cancer

Open Label Study to Assess Efficacy and Safety of Olaparib in Confirmed Genetic BRCA1 or BRCA2 Mutation Pats

BMN 673 (Talazoparib), an Oral PARP Inhibitor, in People With Deleterious BRCA1/2 Mutation-Associated Ovarian Cancer Who Have Had Prior PARP Inhibitor Treatment

A Study to Determine the Safety of BTP-114 for Treatment in Patients With Advanced Solid Tumors With BRCA Mutations

Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid Tumors

Veliparib, Cisplatin, and Vinorelbine Ditartrate in Treating Patients With Recurrent and/or Metastatic Breast Cancer